<< Back to the abstract archive
Case Series: Prolonged Allograft Survival in Two Immunosuppressed Patients
Kristen Hardy, Cody Mullens, Ian McCulloch, Cristiane M. Ueno, MD; Ernest K. Manders, MD, A. Corde Mason, MD
West Virginia University
2018-02-01
Presenter: Cody Mullens
Affidavit:
I certify that the material proposed for presentation in this abstract has not been published in any scientific journal or previously presented at a major meeting. The submitting and presenting author of the work for this project has been predominately been accomplished through their efforts. He conceived and developed the majority of the study design with assistance of the faculty and resident co-authors, acquired most, analyzed all and interpreted all data and was responsible for the majority of drafting the abstract text with the assistance and guidance of the more senior authors on the abstract.
Director Name: Aaron Corde Mason, MD
Author Category: Medical Student
Presentation Category: Clinical
Abstract Category: General Reconstruction
Gamma-irradiated human skin allograft is an acellular, preserved cadaveric dermal skin substitute that is useful as temporary wound coverage to minimize fluid and protein loss1. It is largely regarded as a temporary intervention due to their antigenicity, which usually leads to rejection. This case series demonstrates the prolonged viability of GammaGraft for use as long-term wound coverage in two chronically immunocompromised patients. The cases include two patients who are on immunosuppressive chemotherapy regimens. As of January 2018, both patients have shown prolonged survival of their GammaGraft for 5-7 months. Additionall,y in both patients, the GammaGraft has maintained adherence, vascularization, and epithelialization, serving as a long term means of wound coverage. These patients, who are receiving chronic immunosuppressive therapy or are living in a chronically immunosuppressed state, are unique in the sense that GammaGraft may be used for long-term wound coverage. This series demonstrates the utility of GammaGraft as a viable option for long-term and perhaps permanent wound coverage in immunosuppressed patient populations.
